|Coordinate||91,499,885 bp (GRCm38)|
|Base Change||A ⇒ C (forward strand)|
|Gene Name||interferon (alpha and beta) receptor 1|
|Synonym(s)||Ifar, Ifrc, IFN-alpha/betaR|
|Chromosomal Location||91,485,238-91,507,441 bp (+)|
FUNCTION: [Summary is not available for the mouse gene. This summary is for the human ortholog.] The protein encoded by this gene is a type I membrane protein that forms one of the two chains of a receptor for interferons alpha and beta. Binding and activation of the receptor stimulates Janus protein kinases, which in turn phosphorylate several proteins, including STAT1 and STAT2. The encoded protein also functions as an antiviral factor. [provided by RefSeq, Jul 2008]
PHENOTYPE: Homozygotes for targeted null mutations exhibit increased susceptibility to viral infection, elevated levels of myeloid lineage cells in the peripheral blood and bone marrow, and reduced immune response to immunostimulatory DNA. [provided by MGI curators]
|Amino Acid Change||Threonine changed to Proline|
|Institutional Source||Beutler Lab|
|Gene Model||not available|
AA Change: T341P
|Predicted Effect||probably damaging
PolyPhen 2 Score 0.977 (Sensitivity: 0.76; Specificity: 0.96)
AA Change: T341P
|Predicted Effect||probably damaging
PolyPhen 2 Score 0.977 (Sensitivity: 0.76; Specificity: 0.96)
|Predicted Effect||probably benign|
|Predicted Effect||probably benign|
|Predicted Effect||probably benign|
|Alleles Listed at MGI|
|Mode of Inheritance||Autosomal Recessive|
|Local Stock||Live Mice, Sperm, gDNA|
|Last Updated||2018-11-07 12:11 PM by Diantha La Vine|
Macro-1 was discovered in an ex vivo macrophage screen for control of viral infection. Macrophages from ENU-mutagenized G3 mice were infected with mouse cytomegalovirus (MCMV), influenza virus, Rift Valley Fever virus (RVFV), and an adenoviral vector and examined for effective viral clearance. Peritoneal macrophages from macro-1 mice are highly permissive to MCMV, influenza, RVFV (Figure 1) and adenoviral infection. These macrophages produce normal amounts of tumor necrosis factor (TNF)-α after Toll-like receptor (TLR) stimulation (TLR Signaling Screen).
Preliminary results suggest that mutant macrophages produce lower levels of type I interferons (IFNs) than wild type macrophages upon adenovirus infection. This result needs confirmation.
|Nature of Mutation|
The Ifnar1 gene on chromosome 16 of macro-1 mice was sequenced, and an A to C transversion was identified in exon 8 (of 11 total exons) at position 1115 of the Ifnar1 transcript.
The mutated nucleotide is indicated in red lettering, and results in a conversion of threonine to proline at residue 341 of the IFNAR1 protein.
The IFNAR receptor is typical of class II hCRs and lacks intrinsic kinase activity. Instead, the intracellular domains of the IFNAR receptor subunits are associated with Janus activating kinases (JAKs) that phosphorylate receptors and signal transducing molecules [reviewed in (14;15)] (see Background). In particular, IFNAR1 binds to tyrosine kinase 2 (TYK2) at amino acids 474-498 (16-18). This binding domain contains a proline-rich sequence (box 2 motif) that has been shown in other receptors to recruit and activate tyrosine kinases (16). IFNAR1 has a similar motif at amino acids 461-466 (box 1), but this has only a minor role in TYK2 recruitment (17). IFNAR1 contains several tyrosine residues that become phosphorylated by activated TYK2, and then are able to recruit signal transduction molecules such as signal transducer and activator of transcription (STAT)1 (see the records for domino and poison) and STAT2 (19;20). However, mutational analysis of these tyrosine residues in mouse IFNAR1 suggests that these residues are not necessary for type I IFN activity (18), although it remains possible that phosphorylation of other tyrosine residues may provide STAT docking sites on mouse IFNAR1. IFNAR1 also associates with negative regulators of type I IFN signaling such as suppressor of cytokine signaling 1 (SOCS1) (21).
Several splice variants of human IFNAR1 have been identified in cell lines (22;23), but other data suggests that normal cells only express full-length IFNAR1 (2). Two of these alternative splice variants may produce proteins that lack the transmembrane domain (22), while one is predicted to produce a protein that lacks the amino-terminal region as well as a portion of SD2 (23). It is possible these aberrant IFNAR1 transcripts are expressed only in particular tumor cell lines.
The residue mutated in macro-1 mice is in the extracellular SD4 domain of the IFNAR1 protein. It is unknown whether this protein is expressed and localized normally.
The Ifnar1 mRNA transcript is expressed in all tissues and organs and most cell lines (2;24). In mice, the thymus, bone marrow, testes, embryonic day (E) 10 placenta, L929 cells and spleen had higher levels of Ifnar1 mRNA than other tissues (24). The IFNAR receptor is localized to caveolae on the plasma membrane where there is a concentration of cytoplasmically oriented signaling molecules (25), but is subject to ligand-induced internalization and lysosomal degradation (26).
Type I IFNs are a critical class of cytokines that have potent antiviral, growth-inhibitory and immunomodulatory functions [reviewed in (1;27)]. Classically, the production of type I IFNs (notably IFN-α/β) in response to viral infections is considered to be essential for antiviral defense, a role highlighted by the phenotype of Ifnar1 knockout mice that lack type I IFN signaling (28;29). These mice display high susceptibility to viral infection by vesicular stomatitis virus (VSV), Semliki Forest virus (SFV), Vaccinia virus, lymphocytic choriomeningitis virus (LCMV) and mouse cytomegalovirus (MCMV). The production of type I IFNs in response to viral infection leads to inhibition of viral propagation and increases the vulnerability of infected cells to virus-induced apoptosis (30), a mechanism that is suggested to limit viral spread and may also increase the delivery of antigen to professional antigen-presenting cells (APCs) and be important to the onset of adaptive immunity. Type I IFNs activate natural killer (NK) cells, macrophages and dendritic cells (DCs), all of which play an essential role in the innate immune system (31;32). In addition to their antiviral effects, type I IFNs are also produced in response to infection with bacterial pathogens and have an important role in the host response to bacterial infection [reviewed by (33)]. IFNAR1-deficient mice display susceptibility to some bacterial infections, although they have been shown to be resistant to others including Listeria monocytogenes (33-35). The antiproliferative and apoptotic effects of type I IFNs on macrophages may be the reason why type I IFNs promote susceptibility to certain bacterial infections (36).
All cell types that are susceptible to viral infection are able to release type I IFNs. However, in the immune system, plasmacytoid dendritic cells (pDCs) produce the largest amounts of IFN-α/β in response to nucleic acids derived from pathogenic organisms [reviewed by (37)]. In general, the induction of type I IFN genes is transcriptionally controlled and depends on two members of the IFN regulatory factor (IRF) family, IRF-3 and IRF-7. In response to microbial infections, these factors become phosphorylated, undergo nuclear translocation and induce transcription of genes encoding members of the IFN-α/β family (38). IRF-3 is relatively specific in its induction of the solitary Ifnβ gene; IRF-7 is relatively specific for induction of the Ifnα cluster. Upstream of these events, the recognition of various pathogens leading to type I IFN induction occurs through the toll-like receptors (TLRs) as well as the nucleic-acid cytosolic sensors retinoic acid-inducible gene 1 (RIG-1) and melanoma differentiation-associated protein 5 (MDA5) (39;40). The TLRs engage various adaptors including myeloid differentiation (MyD) 88 (see pococurante and lackadaisical), TIRAP for toll-interleukin 1 receptor domain containing adaptor protein (also called MAL for MyD88 adaptor-like) (see torpid), TRIF for Toll-interleukin 1 receptor (TIR) domain-containing adaptor inducing IFN-β (also known as TICAM-1 for TIR domain-containing adaptor molecule-1) (see Lps2), and TRAM for TRIF related adaptor molecule (also called TICAM-2) (see Tram KO). With the exception of TLR3, which signals solely by activating TRIF, all TLRs recruit MyD88, which triggers signaling pathways leading to nuclear translocation of NF-κB and phosphorylation of IRF-7 (38). Both the MyD88-dependent and TRIF mediated pathways are used by TLR4 (39). The TRIF pathway mediates the phosphorylation of IRF-3 by activating the TANK-binding kinase 1 (TBK1) and IκB kinase (IKK)-i/ε (41). Interestingly, pDCs produce both IFN-α/β, while conventional or myeloid DCs produce only IFN-β. Differences in expression of the receptors that sense viral components play a major role in these differences (37). TLR7 and TLR9 are the critical sensing components in pDCs and result in the activation of the MyD88/IRF-7 pathway in the endosomal compartment, while type I IFN production in cDCs is generally MyD88-independent/IRF-3 dependent and occurs through TLR3, TLR4 and the nucleic-acid cytosolic sensors (15;37).
In addition to the positive feedback loop mediated by ISGF3-induction of IRF-7, constitutively low levels of IFN-α/β have been found to be expressed in several cell types and appear to be a prerequisite for enhanced production of type I IFNs in response to stimuli. These low levels of IFN-α/β do not significantly activate downstream signaling events through IFNAR, but they do maintain tyrosine phosphorylation on IFNAR1, allowing for more efficient recruitment of STAT1 (25). Basal levels of IFN-α/β are also correlated with IRF-7 expression, providing another mechanism for more efficient induction of type I IFN upon infection (15). Constitutive IFN-α/β signaling appears to be required for more efficient type II IFN (IFN-γ) signaling as IFNAR1-deficient cells have a defective IFN-γ response associated with impaired dimerization of STAT1. IFNAR1 has been shown to physically interact with a type II IFN receptor subunit (IFNGR2) in the plasma membrane, thus maintenance of the STAT docking sites on IFNAR1 are probably important for IFN-γ signaling as well (25).
Unique among all the cytokines, type I IFNs are able to promote the activation of all seven STAT family members resulting in the formation of a number of homo- and heterodimer combinations and differing gene induction responses. The particular STAT(s) activated, STAT complexes formed, and the biological activities evoked are dependent on a variety of factors including cell type, cytokine milieu and stimulus [reviewed in (27)]. Indeed, some of the particular STATs have opposing activities and may compete with each other for binding to IFNAR and other STATs. For instance, activated STAT1 is known to promote antiproliferative and apoptotic effects (47), while STAT4 promotes survival and proliferation in CD8+ T cells, particularly those with low levels of STAT1 (48-50). In CD4+ T cells, activation of STAT3 and 5 in the presence of low STAT1 levels is necessary for the antiapoptotic and mitogenic effects of type I IFN (47), although STAT3 has also been shown to mediate apoptotic effects in still other cell types (51). Unlike T cells, the activation of STAT1 in NK cells does not promote apoptosis, but is necessary for NK cytotoxicity (52). Through these opposing effects, type I IFNs can mediate both the destruction of virally infected cells, while promoting the function of cells that are critical for mounting an appropriate immune response.
In addition to the classical JAK-STAT pathway, type I IFN signaling through IFNAR is able to induce several other pathways that can act either in conjunction with STATs or independently [reviewed in (14;27)] (Figure 2). For instance, some IRF family members can induce gene transcription independently of STATs in response to type I IFN signaling (ie IRF-1; mutated in Endeka) (53). Additionally, type I IFN signaling activates p38 mitogen-activated protein kinase (MAPK), phosphatidylinositol (PI) 3-kinase (PI3K), and extracellular signal regulated kinase (ERK), kinases that are known to be involved in the activation of a variety of critical factors including the transcription factors NF-κB and activator protein (AP)-1, as well as the serine/threonine kinases protein kinase B (PKB or Akt) and the mammalian target of rapamycin (MTOR). Indeed, NF-κB is activated by type I IFNs both through the classical NF-κB pathway involving the IκB kinase (IKK) complex as well as an alternative pathway involving NF-κB inducing kinase (NIK) and TNF receptor associated factor(TRAF) 2 (see the record for panr2). TRAF2 is able to directly interact with IFNAR1, and is important for the antiviral effects of type I IFN (54). All of these pathways have been shown to be critical for many of the biological effects of type I IFNs including growth inhibition and antiviral responses.
The responses to type I IFNs are negatively regulated by several mechanisms. These include dephosphorylation of critical tyrosine residues on the receptor subunits as well as receptor internalization and degradation. Other mechanisms include dephosphorylation of JAKs and STATs by several phosphatases. In addition, the association of IFNAR1 with SOCS1 prevents the tyrosine phosphorylation of STATs (21). Further downstream, the inhibition of STAT functions in the nucleus by protein inhibitors of activated STATs (PIAS) proteins occurs (55). Many viruses have similarly found a way to prevent host antiviral responses by producing factors that inhibit the production of type I IFNs as well as type I IFN signaling [reviewed in (15)]. For example, poxvirus encodes a soluble protein that binds with high affinity to type I IFNs, thus neutralizing type I IFN signaling (56), while the V proteins of paramyxoviruses prevent the activation of STAT proteins through a variety of mechanisms including proteasomal degradation, inhibition of phosphorylation, sequestration, and blockage of nuclear translocation (15).
Due to their potent antiviral and anti-proliferative effects, type I IFNs are widely used to treat certain viral infections and cancers. In addition, type I IFNs have been found to play important roles in the etiology of some autoimmune diseases [reviewed in (43)]. Type I IFNs are widely used for the treatment of multiple sclerosis (MS), a chronic autoimmune demyelinating disease characterized by the infiltration of inflammatory cells such as macrophages and T cells into the CNS, resulting in the destruction of axonal myelin sheaths (57). In an animal model of MS, animals deficient in IFN-β or IFNAR1 show an increased level of disease (58-60). The mechanisms underlying this involvement are not well understood, but appear to involve TRIF-dependent induction of type I IFN and subsequent inhibition of the development of a certain T cell subtype (Th17 cells) through IFNAR-dependent signaling in macrophages (59). Although another study studying IFNAR1-deficient mice in the same animal model of MS did not find a connection with Th17 cells, the absence of IFNAR1 on myeloid cells specifically led to severe disease and increased lethality (60). Mice with a B or T cell-specific IFNAR1 deficiency did not show increased disease levels. These results suggest that type I IFN signaling through IFNAR in myeloid cells plays a protective role against the development of multiple sclerosis. By contrast, excess type I IFNs and IFN-stimulated gene expression have been linked to the pathogenesis of other autoimmune diseases such as systemic lupus erythematosus (SLE) and insulin-dependent diabetes mellitus (IDDM) [reviewed by (43)]. Furthermore, IFN-α treatment for viral infections and tumors can sometimes induce these diseases as well as other autoimmune symptoms. The mechanisms behind these effects are not well understood, but likely include enhanced DC maturation and function, promotion of T and B cell differentiation, proliferation and survival, and changes in cytokine expression (43).
Polymorphisms in the human IFNAR1 gene have been implicated in a number of diseases [reviewed in (2)], including protection or susceptibility against cerebral malaria (61), susceptibility to multiple sclerosis (62), as well as susceptibility to various viruses such as human immunodeficiency virus (HIV) (63), and hepatitis C (64). Cells from Down syndrome patients are more sensitive to type I IFN treatment due to trisomy of Chromosome 21, which carries the IFNAR1 and IFNAR2 genes. Accordingly, patients with Down syndrome have an aberrant immune response (65). Human deficiencies in proteins that are involved in the type I IFN response, including various STATs (see records for domino and poison) and TYK2, result in immunodeficiency (66-68). TYK2 deficiency in humans confirms the essential role TYK2 plays in type I IFN signaling, in contrast to results from mice that suggests that TYK2 plays a minor role in the type I IFN response (69).
As the macro-1 mutant was discovered in an ex vivo macrophage screen, it is not known whether macro-1 mice have a similar phenotype to those of Ifnar1 knockout animals. The high permissiveness of macro-1 macrophages to viral infection suggests that IFNAR function in these cells is severely affected and that the macro-1 mutation may be equivalent to a severely hypomorphic or null allele. However, it is not known whether other cell types such as NK cells and DCs will show a similar phenotype. Preliminary results suggest that macro-1 macrophages also produce lower levels of type I IFN relative to wild type macrophages upon viral infection, perhaps due to the lack of the positive feedback loop through IRF-7 . Again, this data suggests that the macro-1 mutation abrogates all type I IFN signaling through the IFNAR receptor.
The macro-1 mutation affects amino acid 341 of the IFNAR1 extracellular domain. This residue occurs in SD4, which is critical for proper formation of the IFNAR complex but does not play a role in ligand-binding (8;9;12). Although amino acid 341 is not conserved amongst species, it is present in the first β-strand (β1) of the SD4 domain. As prolines are known to disrupt secondary structure (70), the substitution of a proline for a threonine at this position may disrupt the conformation of the β1 strand of SD4 and affect the ability of the entire receptor to form a proper ternary complex.
|Primers||Primers cannot be located by automatic search.|
Macro-1 genotyping is performed by amplifying the region containing the mutation using PCR, followed by sequencing of the amplified region to detect the single nucleotide change.
Primers for PCR amplification
Macro-1(F): 5’- AGAACAGCTTGCCACTTCACTGG -3’
Macro-1(R): 5’- GCAGAGAAGCCTTAGCCTTAGAAGAAC -3’
PCR program (use SIGMA JumpStart REDTaq)
1) 94°C 2:00
2) 94°C 0:30
3) 56°C 0:30
4) 72°C 1:00
5) repeat steps (2-4) 29X
6) 72°C 7:00
7) 4°C ∞
Primers for sequencing
Macro_seq(F): 5’- CCCAGGGTAGCTTCAAACTTATG -3’
Macro_seq(R): 5’- TCACAAAGTTCCTGGGTAGC -3’
The following sequence of 1717 nucleotides (from Genbank genomic region NC_000082 for linear DNA sequence of Ifnar1) is amplified:
13961 agaacagctt gccacttcac 13981 tgggaattcc ccacacactc tagagcaccc gtggccttcc tttgttgggg atctgtgtct 14041 cctccattgt accaggagtt ccctaagtgg ggaaactgcc ctcaggtcca cagtgcttac 14101 tacagtgtct taggtattat agagcctcag tacatagtga attaattcat gattggattg 14161 gattttgttt ttgctttctg ttttcaaagt ggctattcaa aaagcagttc tggaagccgt 14221 tcagataaat ggaaaccaat accaacctgt gcaaatgtcc agactacgca ctgtgtcttt 14281 tctcaagata ctgtctacac aggaacgttc tttctccatg tacaagcctc agagggaaat 14341 cacacatcct tttggtctga agagaagttt attgattctc aaaaacacag taagccgagt 14401 tttctttgag acagtctgac actgtagccc aggctggcct ggaactcacg gtgtagccca 14461 gggtagcttc aaacttatgg cagtcctcct gcctgagctc ctgagagctg aggttgtggg 14521 tgtggtccat gcctgctgta tagcaagcgc tttctggagt gtaattcctc atgtagggcg 14581 agtcccggaa ggttgtttga aggtgtctta gtgtgcaatt tctgtttgca ttcttcccca 14641 gttctccctc ctcctccggt cattactgtc accgccatga gtgacacctt gcttgtttat 14701 gtcaactgtc aggacagcac atgtgatgga ctcaattacg aaatcatctt ttgggaaaac 14761 acttccaata ctaaggtaaa aagctaccca ggaactttgt gacttagcct cataccggtg 14821 atgatgggaa agaaagttag tgggggaggg agggcaagag caagcagtca cagctctaag 14881 gtttgggagg ccttttaatc ttgatggtgg cctgtctgca gtagagcgaa tgtcagcctt 14941 ttccatggtc tgcatgacag tacaggtcgc ctgcatctgg gcctgacttt tctgtgtgtg 15001 aatatacagg agtgtgtgca agcatgtgtg tgtgtgtgtg tgtgtgtgtg tgtgtgtgtg 15061 tgtgtgtgtg tgtgactgtg catgagtatg tgaatgtatg tatgtgtgaa tatatgtgtg 15121 tgtatgtgtg aatgtacgtg tgtgtgtatg agtgtatgtg tgtgtgtgag tgtatgtgtg 15181 aatgtgtggg aggatgtgtg tgtgtgtgtg tgtgtgtgtg tgtgtgagtg actctccgtg 15241 agtatgtgag tatatgtatg tgaatctgtg tgaatgtgtg tgaggatgtg agtgtaagtg 15301 tgtgtgtgtg tgtgtgaatg actttgcatg agtatgtgtg tgtatatatg tgtgaatgta 15361 cgtgtttgtg tgtgtgtgtg tgtgtgtgtg tgtgtgtgag gatgtgaatg tgcgtgtgcg 15421 cgtgtgtgtt gacaattgct tatgtactat atgttcatca caggacactc atggcggcca 15481 gacgataagc tgtggaagtg agctctctct cctgccttat aactcccggg gattgaatta 15541 agtcatcagg ttttgcagca agcatcctta tgtactaggc catcttgatt ttcaactata 15601 tcttgagcct cctactgctg aattagaacc attattacac tttcccaagt gttcttctaa 15661 ggctaaggct tctctgc
PCR primer binding sites are underlined; sequencing primer binding sites are highlighted in gray; the mutated A is shown in red text.
1. Pestka, S., Krause, C. D., and Walter, M. R. (2004) Interferons, interferon-like cytokines, and their receptors, Immunol. Rev. 202, 8-32.
2. de Weerd, N. A., Samarajiwa, S. A., and Hertzog, P. J. (2007) Type I interferon receptors: biochemistry and biological functions, J Biol. Chem. 282, 20053-20057.
3. Uze, G., Di, M. S., Mouchel-Vielh, E., Monneron, D., Bandu, M. T., Horisberger, M. A., Dorques, A., Lutfalla, G., and Mogensen, K. E. (1994) Domains of interaction between alpha interferon and its receptor components, J Mol. Biol. 243, 245-257.
4. Runkel, L., deDios, C., Karpusas, M., Betzenhauser, M., Muldowney, C., Zafari, M., Benjamin, C. D., Miller, S., Hochman, P. S., and Whitty, A. (2000) Systematic mutational mapping of sites on human interferon-beta-1a that are important for receptor binding and functional activity, Biochemistry 39, 2538-2551.
5. Bazan, J. F. (1990) Structural design and molecular evolution of a cytokine receptor superfamily, Proc. Natl. Acad. Sci. U. S. A 87, 6934-6938.
6. Cutrone, E. C. and Langer, J. A. (2001) Identification of critical residues in bovine IFNAR-1 responsible for interferon binding, J Biol. Chem. 276, 17140-17148.
7. Jaks, E., Gavutis, M., Uze, G., Martal, J., and Piehler, J. (2007) Differential receptor subunit affinities of type I interferons govern differential signal activation, J Mol. Biol. 366, 525-539.
8. Lamken, P., Gavutis, M., Peters, I., Van der, H. J., Uze, G., and Piehler, J. (2005) Functional cartography of the ectodomain of the type I interferon receptor subunit ifnar1, J Mol. Biol. 350, 476-488.
9. Li, Z., Strunk, J. J., Lamken, P., Piehler, J., and Walz, T. (2008) The EM structure of a type I interferon-receptor complex reveals a novel mechanism for cytokine signaling, J Mol. Biol. 377, 715-724.
10. Cajean-Feroldi, C., Nosal, F., Nardeux, P. C., Gallet, X., Guymarho, J., Baychelier, F., Sempe, P., Tovey, M. G., Escary, J. L., and Eid, P. (2004) Identification of residues of the IFNAR1 chain of the type I human interferon receptor critical for ligand binding and biological activity, Biochemistry 43, 12498-12512.
11. Lu, J., Chuntharapai, A., Beck, J., Bass, S., Ow, A., de Vos, A. M., Gibbs, V., and Kim, K. J. (1998) Structure-function study of the extracellular domain of the human IFN-alpha receptor (hIFNAR1) using blocking monoclonal antibodies: the role of domains 1 and 2, J Immunol. 160, 1782-1788.
12. Strunk, J. J., Gregor, I., Becker, Y., Li, Z., Gavutis, M., Jaks, E., Lamken, P., Walz, T., Enderlein, J., and Piehler, J. (2008) Ligand binding induces a conformational change in ifnar1 that is propagated to its membrane-proximal domain, J Mol. Biol. 377, 725-739.
13. Ghislain, J., Lingwood, C. A., and Fish, E. N. (1994) Evidence for glycosphingolipid modification of the type 1 IFN receptor, J Immunol. 153, 3655-3663.
14. Platanias, L. C. (2005) Mechanisms of type-I- and type-II-interferon-mediated signalling, Nat. Rev. Immunol. 5, 375-386.
15. Takaoka, A. and Yanai, H. (2006) Interferon signalling network in innate defence, Cell Microbiol. 8, 907-922.
16. Colamonici, O., Yan, H., Domanski, P., Handa, R., Smalley, D., Mullersman, J., Witte, M., Krishnan, K., and Krolewski, J. (1994) Direct binding to and tyrosine phosphorylation of the alpha subunit of the type I interferon receptor by p135tyk2 tyrosine kinase, Mol. Cell Biol. 14, 8133-8142.
17. Yan, H., Krishnan, K., Lim, J. T., Contillo, L. G., and Krolewski, J. J. (1996) Molecular characterization of an alpha interferon receptor 1 subunit (IFNaR1) domain required for TYK2 binding and signal transduction, Mol. Cell Biol. 16, 2074-2082.
18. Zhao, W., Lee, C., Piganis, R., Plumlee, C., de, W. N., Hertzog, P. J., and Schindler, C. (2008) A conserved IFN-alpha receptor tyrosine motif directs the biological response to type I IFNs, J Immunol. 180, 5483-5489.
19. Yan, H., Krishnan, K., Greenlund, A. C., Gupta, S., Lim, J. T., Schreiber, R. D., Schindler, C. W., and Krolewski, J. J. (1996) Phosphorylated interferon-alpha receptor 1 subunit (IFNaR1) acts as a docking site for the latent form of the 113 kDa STAT2 protein, EMBO J 15, 1064-1074.
20. Li, X., Leung, S., Kerr, I. M., and Stark, G. R. (1997) Functional subdomains of STAT2 required for preassociation with the alpha interferon receptor and for signaling, Mol. Cell Biol. 17, 2048-2056.
21. Fenner, J. E., Starr, R., Cornish, A. L., Zhang, J. G., Metcalf, D., Schreiber, R. D., Sheehan, K., Hilton, D. J., Alexander, W. S., and Hertzog, P. J. (2006) Suppressor of cytokine signaling 1 regulates the immune response to infection by a unique inhibition of type I interferon activity, Nat. Immunol. 7, 33-39.
22. Abramovich, C., Ratovitski, E., Lundgren, E., and Revel, M. (1994) Identification of mRNAs encoding two different soluble forms of the human interferon alpha-receptor, FEBS Lett 338, 295-300.
23. Cook, J. R., Cleary, C. M., Mariano, T. M., Izotova, L., and Pestka, S. (1996) Differential responsiveness of a splice variant of the human type I interferon receptor to interferons, J Biol. Chem. 271, 13448-13453.
24. Hardy, M. P., Hertzog, P. J., and Owczarek, C. M. (2002) Multiple regions within the promoter of the murine Ifnar-2 gene confer basal and inducible expression, Biochem. J 365, 355-367.
25. Takaoka, A., Mitani, Y., Suemori, H., Sato, M., Yokochi, T., Noguchi, S., Tanaka, N., and Taniguchi, T. (2000) Cross talk between interferon-gamma and -alpha/beta signaling components in caveolar membrane domains, Science 288, 2357-2360.
26. Marijanovic, Z., Ragimbeau, J., Kumar, K. G., Fuchs, S. Y., and Pellegrini, S. (2006) TYK2 activity promotes ligand-induced IFNAR1 proteolysis, Biochem. J 397, 31-38.
27. van Boxel-Dezaire, A. H., Rani, M. R., and Stark, G. R. (2006) Complex modulation of cell type-specific signaling in response to type I interferons, Immunity 25, 361-372.
28. Hwang, S. Y., Hertzog, P. J., Holland, K. A., Sumarsono, S. H., Tymms, M. J., Hamilton, J. A., Whitty, G., Bertoncello, I., and Kola, I. (1995) A null mutation in the gene encoding a type I interferon receptor component eliminates antiproliferative and antiviral responses to interferons alpha and beta and alters macrophage responses, Proc. Natl. Acad. Sci. U. S A 92, 11284-11288.
29. Muller, U., Steinhoff, U., Reis, L. F., Hemmi, S., Pavlovic, J., Zinkernagel, R. M., and Aguet, M. (1994) Functional role of type I and type II interferons in antiviral defense, Science 264, 1918-1921.
30. Tanaka, N., Sato, M., Lamphier, M. S., Nozawa, H., Oda, E., Noguchi, S., Schreiber, R. D., Tsujimoto, Y., and Taniguchi, T. (1998) Type I interferons are essential mediators of apoptotic death in virally infected cells, Genes Cells 3, 29-37.
31. Pestka, S., Langer, J. A., Zoon, K. C., and Samuel, C. E. (1987) Interferons and their actions, Annu. Rev. Biochem. 56, 727-777.
32. Biron, C. A., Nguyen, K. B., Pien, G. C., Cousens, L. P., and Salazar-Mather, T. P. (1999) Natural killer cells in antiviral defense: function and regulation by innate cytokines, Annu. Rev. Immunol. 17, 189-220.
33. Decker, T., Muller, M., and Stockinger, S. (2005) The yin and yang of type I interferon activity in bacterial infection, Nat. Rev. Immunol. 5, 675-687.
34. Auerbuch, V., Brockstedt, D. G., Meyer-Morse, N., O'Riordan, M., and Portnoy, D. A. (2004) Mice lacking the type I interferon receptor are resistant to Listeria monocytogenes, J Exp. Med. 200, 527-533.
35. O'Connell, R. M., Saha, S. K., Vaidya, S. A., Bruhn, K. W., Miranda, G. A., Zarnegar, B., Perry, A. K., Nguyen, B. O., Lane, T. F., Taniguchi, T., Miller, J. F., and Cheng, G. (2004) Type I interferon production enhances susceptibility to Listeria monocytogenes infection, J Exp. Med. 200, 437-445.
36. Qiu, H., Fan, Y., Joyee, A. G., Wang, S., Han, X., Bai, H., Jiao, L., Van, R. N., and Yang, X. (2008) Type I IFNs enhance susceptibility to Chlamydia muridarum lung infection by enhancing apoptosis of local macrophages, J Immunol. 181, 2092-2102.
37. Kaisho, T. (2008) Type I interferon production by nucleic acid-stimulated dendritic cells, Front Biosci. 13, 6034-6042.
38. Honda, K., Ohba, Y., Yanai, H., Negishi, H., Mizutani, T., Takaoka, A., Taya, C., and Taniguchi, T. (2005) Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction, Nature 434, 1035-1040.
39. Kawai, T. and Akira, S. (2006) Innate immune recognition of viral infection, Nat. Immunol. 7, 131-137.
40. Rothenfusser, S., Goutagny, N., Diperna, G., Gong, M., Monks, B. G., Schoenemeyer, A., Yamamoto, M., Akira, S., and Fitzgerald, K. A. (2005) The RNA Helicase Lgp2 Inhibits TLR-Independent Sensing of Viral Replication by Retinoic Acid-Inducible Gene-I, J. Immunol. 175, 5260-5268.
41. Sharma, S., tenOever, B. R., Grandvaux, N., Zhou, G. P., Lin, R., and Hiscott, J. (2003) Triggering the interferon antiviral response through an IKK-related pathway, Science 300, 1148-1151.
42. Ragimbeau, J., Dondi, E., Alcover, A., Eid, P., Uze, G., and Pellegrini, S. (2003) The tyrosine kinase Tyk2 controls IFNAR1 cell surface expression, EMBO J 22, 537-547.
43. Theofilopoulos, A. N., Baccala, R., Beutler, B., and Kono, D. H. (2005) Type I Interferons (a/b) in Immunity and Autoimmunity, Annu. Rev. Immunol.
44. Marie, I., Durbin, J. E., and Levy, D. E. (1998) Differential viral induction of distinct interferon-alpha genes by positive feedback through interferon regulatory factor-7, EMBO J 17, 6660-6669.
45. Sato, M., Hata, N., Asagiri, M., Nakaya, T., Taniguchi, T., and Tanaka, N. (1998) Positive feedback regulation of type I IFN genes by the IFN-inducible transcription factor IRF-7, FEBS Lett 441, 106-110.
46. Decker, T., Lew, D. J., and Darnell, J. E., Jr. (1991) Two distinct alpha-interferon-dependent signal transduction pathways may contribute to activation of transcription of the guanylate-binding protein gene, Mol. Cell Biol. 11, 5147-5153.
47. Tanabe, Y., Nishibori, T., Su, L., Arduini, R. M., Baker, D. P., and David, M. (2005) Cutting edge: role of STAT1, STAT3, and STAT5 in IFN-alpha beta responses in T lymphocytes, J Immunol. 174, 609-613.
48. Curtsinger, J. M., Valenzuela, J. O., Agarwal, P., Lins, D., and Mescher, M. F. (2005) Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation, J Immunol. 174, 4465-4469.
49. Garcia-Sastre, A. and Biron, C. A. (2006) Type 1 interferons and the virus-host relationship: a lesson in detente, Science 312, 879-882.
50. Gil, M. P., Salomon, R., Louten, J., and Biron, C. A. (2006) Modulation of STAT1 protein levels: a mechanism shaping CD8 T-cell responses in vivo, Blood 107, 987-993.
51. Gamero, A. M., Potla, R., Wegrzyn, J., Szelag, M., Edling, A. E., Shimoda, K., Link, D. C., Dulak, J., Baker, D. P., Tanabe, Y., Grayson, J. M., and Larner, A. C. (2006) Activation of Tyk2 and Stat3 is required for the apoptotic actions of interferon-beta in primary pro-B cells, J Biol. Chem. 281, 16238-16244.
52. Liang, S., Wei, H., Sun, R., and Tian, Z. (2003) IFNalpha regulates NK cell cytotoxicity through STAT1 pathway, Cytokine 23, 190-199.
53. Wong, L. H., Sim, H., Chatterjee-Kishore, M., Hatzinisiriou, I., Devenish, R. J., Stark, G., and Ralph, S. J. (2002) Isolation and characterization of a human STAT1 gene regulatory element. Inducibility by interferon (IFN) types I and II and role of IFN regulatory factor-1, J Biol. Chem. 277, 19408-19417.
54. Yang, C. H., Murti, A., Pfeffer, S. R., Fan, M., Du, Z., and Pfeffer, L. M. (2008) The role of TRAF2 binding to the type I interferon receptor in alternative NF kappaB activation and antiviral response, J Biol. Chem. 283, 14309-14316.
55. Chung, C. D., Liao, J., Liu, B., Rao, X., Jay, P., Berta, P., and Shuai, K. (1997) Specific inhibition of Stat3 signal transduction by PIAS3, Science 278, 1803-1805.
56. Symons, J. A., Alcami, A., and Smith, G. L. (1995) Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity, Cell 81, 551-560.
58. Teige, I., Treschow, A., Teige, A., Mattsson, R., Navikas, V., Leanderson, T., Holmdahl, R., and Issazadeh-Navikas, S. (2003) IFN-beta gene deletion leads to augmented and chronic demyelinating experimental autoimmune encephalomyelitis, J Immunol. 170, 4776-4784.
59. Guo, B., Chang, E. Y., and Cheng, G. (2008) The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice, J Clin. Invest 118, 1680-1690.
60. Prinz, M., Schmidt, H., Mildner, A., Knobeloch, K. P., Hanisch, U. K., Raasch, J., Merkler, D., Detje, C., Gutcher, I., Mages, J., Lang, R., Martin, R., Gold, R., Becher, B., Bruck, W., and Kalinke, U. (2008) Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system, Immunity 28, 675-686.
61. Aucan, C., Walley, A. J., Hennig, B. J., Fitness, J., Frodsham, A., Zhang, L., Kwiatkowski, D., and Hill, A. V. (2003) Interferon-alpha receptor-1 (IFNAR1) variants are associated with protection against cerebral malaria in the Gambia, Genes Immun. 4, 275-282.
62. Leyva, L., Fernandez, O., Fedetz, M., Blanco, E., Fernandez, V. E., Oliver, B., Leon, A., Pinto-Medel, M. J., Mayorga, C., Guerrero, M., Luque, G., Alcina, A., and Matesanz, F. (2005) IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response, J Neuroimmunol. 163, 165-171.
63. Diop, G., Hirtzig, T., Do, H., Coulonges, C., Vasilescu, A., Labib, T., Spadoni, J. L., Therwath, A., Lathrop, M., Matsuda, F., and Zagury, J. F. (2006) Exhaustive genotyping of the interferon alpha receptor 1 (IFNAR1) gene and association of an IFNAR1 protein variant with AIDS progression or susceptibility to HIV-1 infection in a French AIDS cohort, Biomed. Pharmacother. 60, 569-577.
64. Saito, T., Ji, G., Shinzawa, H., Okumoto, K., Hattori, E., Adachi, T., Takeda, T., Sugahara, K., Ito, J. I., Watanabe, H., Saito, K., Togashi, H., Ishii, K., Matsuura, T., Inageda, K., Muramatsu, M., and Kawata, S. (2004) Genetic variations in humans associated with differences in the course of hepatitis C, Biochem. Biophys. Res. Commun. 317, 335-341.
65. Kola, I. and Hertzog, P. J. (1997) Animal models in the study of the biological function of genes on human chromosome 21 and their role in the pathophysiology of Down syndrome, Hum. Mol. Genet 6, 1713-1727.
66. Dupuis, S., Jouanguy, E., Al-Hajjar, S., Fieschi, C., Al-Mohsen, I. Z., Al-Jumaah, S., Yang, K., Chapgier, A., Eidenschenk, C., Eid, P., Al, G. A., Tufenkeji, H., Frayha, H., Al-Gazlan, S., Al-Rayes, H., Schreiber, R. D., Gresser, I., and Casanova, J. L. (2003) Impaired response to interferon-alpha/beta and lethal viral disease in human STAT1 deficiency, Nat. Genet 33, 388-391.
67. Minegishi, Y., Saito, M., Tsuchiya, S., Tsuge, I., Takada, H., Hara, T., Kawamura, N., Ariga, T., Pasic, S., Stojkovic, O., Metin, A., and Karasuyama, H. (2007) Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome, Nature 448, 1058-1062.
68. Minegishi, Y., Saito, M., Morio, T., Watanabe, K., Agematsu, K., Tsuchiya, S., Takada, H., Hara, T., Kawamura, N., Ariga, T., Kaneko, H., Kondo, N., Tsuge, I., Yachie, A., Sakiyama, Y., Iwata, T., Bessho, F., Ohishi, T., Joh, K., Imai, K., Kogawa, K., Shinohara, M., Fujieda, M., Wakiguchi, H., Pasic, S., Abinun, M., Ochs, H. D., Renner, E. D., Jansson, A., Belohradsky, B. H., Metin, A., Shimizu, N., Mizutani, S., Miyawaki, T., Nonoyama, S., and Karasuyama, H. (2006) Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity, Immunity 25, 745-755.
69. Karaghiosoff, M., Neubauer, H., Lassnig, C., Kovarik, P., Schindler, H., Pircher, H., McCoy, B., Bogdan, C., Decker, T., Brem, G., Pfeffer, K., and Muller, M. (2000) Partial impairment of cytokine responses in Tyk2-deficient mice, Immunity 13, 549-560.
|Science Writers||Nora G. Smart|
|Illustrators||Diantha La Vine|
|Authors||Sungyong Won, Celine Eidenschenk, Bruce Beutler|